Medical Molecular Morphology

, Volume 47, Issue 1, pp 1–7

Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide

Authors

    • Department of NeurosurgeryTeikyo University Chiba Medical Center
  • Mineko Murakami
    • Department of NeurosurgeryTeikyo University Chiba Medical Center
  • Katsumi Hoya
    • Department of NeurosurgeryTeikyo University Chiba Medical Center
  • Shoko M. Yamada
    • Department of NeurosurgeryTeikyo University Chiba Medical Center
  • Shinya Miyamoto
    • Department of NeurosurgeryTeikyo University Chiba Medical Center
  • So Yamada
    • Department of NeurosurgeryTeikyo University Chiba Medical Center
  • Jae-Hyun Son
    • Department of NeurosurgeryTeikyo University Chiba Medical Center
  • Hajime Nishido
    • Department of NeurosurgeryTeikyo University Chiba Medical Center
  • Fuyuaki Ide
    • Department of NeurosurgeryTeikyo University Chiba Medical Center
  • Hiroshi Nagashima
    • Department of NeurosurgeryTeikyo University Chiba Medical Center
  • Mutsumi Sugaya
    • Department of RehabilitationTeikyo University Chiba Medical Center
  • Toshio Hirohata
    • Department of NeurosurgeryTeikyo University Chiba Medical Center
    • Department of NeurosurgeryThe University of Tokyo
  • Akiko Mizutani
    • Department of NeurosurgeryTeikyo University Chiba Medical Center
    • Teikyo Heisei University
  • Hiroko Okinaga
    • Teikyo Heisei University
  • Yudo Ishii
    • Department of NeurosurgeryNippon Medical School
  • Shigeyuki Tahara
    • Department of NeurosurgeryNippon Medical School
  • Akira Teramoto
    • Department of NeurosurgeryNippon Medical School
  • R. Yoshiyuki Osamura
    • Department of PathologyInternational University of Health and Welfare Mita Hospital
Review

DOI: 10.1007/s00795-013-0050-z

Cite this article as:
Matsuno, A., Murakami, M., Hoya, K. et al. Med Mol Morphol (2014) 47: 1. doi:10.1007/s00795-013-0050-z

Abstract

There have been several reports of temozolomide (TMZ) treatment of pituitary carcinomas and atypical adenomas. O6-methyl-guanine-DNA methyltransferase is not the sole molecule determining the sensitivity to TMZ in pituitary carcinomas and atypical adenomas. The Japan Society of Hypothalamic and Pituitary Tumors study suggests that MSH6, one of mismatch repair pathway enzyme, fulfills a contributory role to the efficacy of TMZ treatment for pituitary carcinomas and atypical adenomas. The preserved MSH6 function might be essential for the responsiveness to TMZ treatment in pituitary carcinomas and atypical adenomas.

Keywords

Pituitary carcinomas and atypical adenomasTemozolomideO6-Methyl-guanine-DNA methyltransferaseMismatch repair pathwayMSH6

Copyright information

© The Japanese Society for Clinical Molecular Morphology 2013